Are decreased AdipoR1 mRNA levels associated with adiponectin resistance in coronary artery disease patients?

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 4, 2015, Pages 331-336

  Sopić, Miron ^a   Joksić, Jelena ^a   Spasojević Kalimanovska, Vesna ^a   Kalimanovska Oštrić, Dimitra ^a,b   Andelković, Kristina ^b   Jelić Ivanović, Zorana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Adiponectin; AdipoR1 mRNA; AdipoR2 mRNA; Coronary artery disease

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; TRIACYLGLYCEROL; ADIPONECTIN RECEPTOR; ADIPOQ PROTEIN, HUMAN; ADIPOR1 PROTEIN, HUMAN; ADIPOR2 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE INDEX; HUMAN; INSULIN BLOOD LEVEL; MALE; METABOLIC PARAMETERS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STENOSIS; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CORONARY ARTERY OBSTRUCTION; DOWN REGULATION; GENETICS; MIDDLE AGED; MONONUCLEAR CELL;

ADIPONECTIN; AGED; BIOMARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY STENOSIS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ADIPONECTIN; RNA, MESSENGER;

EID: 84925449659     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12361     Document Type: Article

References (30)

1. Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol. Metab. 2013; 2: 133-41.
2. Fruebis J, Tsao TS, Javorschi S et al. Proteolytic cleavage product of 30-kDa adipocyte complement related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U.S.A. 2001; 98: 2005-10.
3. Palanivel R, Fang X, Park M et al. Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocites. Cardiovasc. Res. 2007; 75: 148-57.
4. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013; 17: 185-96.
5. Holland WL, Miller RA, Wang ZV et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 2011; 17: 55-63.
6. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 2004; 323: 630-5.
7. Lovren F, Pan Y, Quan A et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am. J. Physiol. Heart Circ. Physiol. 2010; 299: H656-63.
8. Hansson GL. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005; 352: 1685-95.
9. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics-2014 update: A report from the American Heart Association. Circulation 2014; 129: 399-410.
10. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
11. Spranger J, Kroke A, Möhlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-8.
12. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999; 257: 79-83.
13. Lee ES, Park S, Kim E et al. Association between adiponectin levels and coronary heart disease and mortality: A systematic review and meta-analysis. Int. J. Epidemiol. 2013; 42: 1029-39.
14. Schnabel R, Messow CM, Lubos E et al. Association of adiponectin with adverse outcome in coronary artery disease patients: Results from the AtheroGene study. Eur. Heart J. 2008; 29: 649-57.
15. Shimano M, Ouchi N, Shibata R et al. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J. Mol. Cell. Cardiol. 2010; 49: 210-20.
16. Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin. Chem. 2006; 52: 853-9.
17. Qiao L, Zou C, Westhuyzen D, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 2008; 57: 1824-33.
18. Tsubakio-Yamamoto K, Matsuura F, Koseki M et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem. Biophys. Res. Commun. 2008; 375: 390-4.
19. Altinova AE, Toruner F, Bukan N et al. Decreased plasma adiponectin is associated with insulin resistance and HDL cholesterol in overweight subjects. Endocr. J. 2007; 54: 221-6.
20. Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-69.
21. Rizza S, Gigli F, Galli A et al. Adiponectin isoforms in elderly patients with or without coronary artery disease. J. Am. Geriatr. Soc. 2010; 58: 702-6.
22. Sattar N, Nelson SM. Adiponectin, diabetes, and coronary heart disease in older persons: Unraveling the paradox. J. Clin. Endocrinol. Metab. 2008; 93: 3299-301.
23. Dekker JM, Funahashi T, Nijpel G et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J. Clin. Endocrinol. Metab. 2008; 93: 1489-96.
24. Kollias A, Tsiotra PC, Ikonomidis I et al. Adiponectin levels and expression of adiponectin receptors in isolated monocytes from overweight patients with coronary artery disease. Cardiovasc. Diabetol. 2011; 10: 14.
25. Weigert J, Neumeier M, Wanninger J et al. Reduced response to adiponectin and lower abundance of adiponectin receptor proteins in type 2 diabetic monocytes. FEBS Lett. 2008; 582: 1777-82.
26. Cui XB, Wang C, Li L et al. Insulin decreases myocardial adiponectin receptor 1 expression via PI3K/Akt and FoxO1 pathway. Cardiovasc. Res. 2012; 93: 69-78.
27. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005; 26: 439-51.
28. Van Berendoncks AM, Garnier A, Beckers P et al. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ. Heart Fail. 2010; 3: 185-94.
29. Hara K, Horikoshi M, Yamauchi T et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29: 1357-62.
30. Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2006; 279: 12152-62.